Literature DB >> 24248815

Intact expression status of RASSF1A in acute myeloid leukemia.

Davood Zare-Abdollahi1, Shamsi Safari, Abolfazl Movafagh, Mojtaba Ghadiani, Sahand Riazi-Isfahani, Mir Davood Omrani.   

Abstract

As a typical tumor suppressor gene, transcriptional silencing of ras-association domain family 1, isoform A (RASSF1A) is caused by biallelic methylation or the condition that one allele is methylated and then the other allele lost by allelic loss, as second hit. RASSF1A is inactivated epigenetically and thus down-regulated in many solid tumors. In summary, for the first time, we analyzed the expression status of RASSF1A in a cohort of 56 de novo acute myeloid leukemia (AML) patients using quantitative real-time polymerase chain reaction. Results of our study indicate that patients with AML exhibited no differences in the RASSF1A gene expression comparing to normal controls. In conclusion, expression status of RASSF1A remained intact in our target samples, indicating that RASSF1A expression variation does not participate in the pathogenesis and the progression of AML.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24248815     DOI: 10.1007/s12032-013-0770-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

1.  MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains.

Authors:  K O Tan; K M Tan; S L Chan; K S Yee; M Bevort; K C Ang; V C Yu
Journal:  J Biol Chem       Date:  2000-11-01       Impact factor: 5.157

2.  The RASSF1A tumor suppressor activates Bax via MOAP-1.

Authors:  Michele D Vos; Ashraf Dallol; Kristin Eckfeld; Nadia P C Allen; Howard Donninger; Luke B Hesson; Diego Calvisi; Farida Latif; Geoffrey J Clark
Journal:  J Biol Chem       Date:  2005-12-12       Impact factor: 5.157

3.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

4.  Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group.

Authors:  N Dastugue; C Payen; M Lafage-Pochitaloff; P Bernard; D Leroux; F Huguet-Rigal; A M Stoppa; G Marit; L Molina; M Michallet
Journal:  Leukemia       Date:  1995-09       Impact factor: 11.528

5.  Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.

Authors:  M F Johan; D T Bowen; M E Frew; A C Goodeve; J T Reilly
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

6.  Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia.

Authors:  M J Greenwood; M D Seftel; C Richardson; D Barbaric; M J Barnett; H Bruyere; D L Forrest; D E Horsman; C Smith; K Song; H J Sutherland; C L Toze; T J Nevill; S H Nantel; D E Hogge
Journal:  Leuk Lymphoma       Date:  2006-07

Review 7.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

8.  Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

Authors:  E Beillard; N Pallisgaard; V H J van der Velden; W Bi; R Dee; E van der Schoot; E Delabesse; E Macintyre; E Gottardi; G Saglio; F Watzinger; T Lion; J J M van Dongen; P Hokland; J Gabert
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

9.  Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia.

Authors:  Ivy H N Wong; Jacqueline Chan; Joyce Wong; Paul K H Tam
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

Review 10.  The role of RASSF1A methylation in cancer.

Authors:  Luke B Hesson; Wendy N Cooper; Farida Latif
Journal:  Dis Markers       Date:  2007       Impact factor: 3.434

View more
  4 in total

1.  PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.

Authors:  Daniela Bräuer-Hartmann; Jens-Uwe Hartmann; Alexander Arthur Wurm; Dennis Gerloff; Christiane Katzerke; Maria Vittoria Verga Falzacappa; Pier Giuseppe Pelicci; Carsten Müller-Tidow; Daniel G Tenen; Dietger Niederwieser; Gerhard Behre
Journal:  Cancer Res       Date:  2015-06-03       Impact factor: 12.701

2.  Valproic acid may exerts its cytotoxic effect through rassf1a expression induction in acute myeloid leukemia.

Authors:  Zare-Abdollahi Davood; Safari Shamsi; Hamid Ghaedi; Riazi-Isfahani Sahand; Ghadyani Mojtaba; Tabarraee Mahdi; Mirfakhraie Reza; Mohammad Javad Ebrahimi; Reyhaneh Sadat Miri-Moosavi; Sara Boosaliki; Omrani Mir Davood
Journal:  Tumour Biol       Date:  2016-02-19

3.  Lack of Altered BECN1 Gene Expression in Iranian Patients with Acute Myeloid Leukemia

Authors:  Ladan Keyvan; Seyed Kazem Bidoki; Davood Zare Abdollahi; Neda Mansouri; Mehrdad Hashemi; Sa Mortazavi Tabatabaei; Hediyeh Fardmanesh; Mansour Meimandi; Seyed Majid Ayatollahi; Hasan Jalaeikhoo; Abolfazl Movafagh
Journal:  Asian Pac J Cancer Prev       Date:  2016-12-01

4.  RASSF1A Site-Specific Methylation Hotspots in Cancer and Correlation with RASSF1C and MOAP-1.

Authors:  Natalia Volodko; Mohamed Salla; Alaa Zare; El-Arbi Abulghasem; Krista Vincent; Matthew G K Benesch; Todd P W McMullen; Oliver F Bathe; Lynne Postovit; Shairaz Baksh
Journal:  Cancers (Basel)       Date:  2016-06-10       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.